Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2016

Date: November 16, 2016
Pages: 210
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GF66C19399DEN
Leaflet:

Download PDF Leaflet

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastrointestinal Stromal Tumor – Pipeline Review, H2 2016, provides an overview of the Gastrointestinal Stromal Tumor (Oncology) pipeline landscape.

Gastrointestinal stromal tumors (GISTs) are tumors, which occur in the gastrointestinal tract. Gastrointestinal stromal tumors belong to a group of cancers called soft tissue sarcoma. GISTs can be benign or malignant tumors. The symptoms of GIST include pain or discomfort in the abdomen, a mass in the abdomen that can feel with the hand, nausea and vomiting, vomiting blood or having blood in the stool and fatigue due to anemia (low red blood cell counts). Gastrointestinal stromal tumor treatment involves the use of surgery, radiation therapy, targeted therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastrointestinal Stromal Tumor – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gastrointestinal Stromal Tumor (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastrointestinal Stromal Tumor (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastrointestinal Stromal Tumor (GIST) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 15, 10, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.Gastrointestinal Stromal Tumor.

Gastrointestinal Stromal Tumor (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastrointestinal Stromal Tumor (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastrointestinal Stromal Tumor (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastrointestinal Stromal Tumor (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastrointestinal Stromal Tumor (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastrointestinal Stromal Tumor (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastrointestinal Stromal Tumor (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastrointestinal Stromal Tumor (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Gastrointestinal Stromal Tumor (GIST) Overview
Therapeutics Development
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Overview
Pipeline Products for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis
Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Development by Companies
Gastrointestinal Stromal Tumor (GIST) - Therapeutics under Investigation by Universities/Institutes
Gastrointestinal Stromal Tumor (GIST) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Gastrointestinal Stromal Tumor (GIST) - Products under Development by Companies
Gastrointestinal Stromal Tumor (GIST) - Products under Investigation by Universities/Institutes
Gastrointestinal Stromal Tumor (GIST) - Companies Involved in Therapeutics Development
AB Science SA
Advanced Accelerator Applications S.A.
Advenchen Laboratories, LLC
Ariad Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
ArQule, Inc.
Array BioPharma Inc.
Astex Pharmaceuticals Inc
Blueprint Medicines Corporation
Boston Biomedical, Inc.
Calithera Biosciences, Inc.
Chipscreen Biosciences Ltd
Daiichi Sankyo Company, Limited
Deciphera Pharmaceuticals, LLC
F. Hoffmann-La Roche Ltd.
Horizon Pharma Plc
Immunicum AB
Jiangsu Hengrui Medicine Co., Ltd.
Kolltan Pharmaceuticals, Inc.
Natco Pharma Limited
Nerviano Medical Sciences S.r.l.
Novartis AG
Omeros Corporation
Plexxikon Inc.
Rhizen Pharmaceuticals S.A.
Taiho Pharmaceutical Co., Ltd.
Gastrointestinal Stromal Tumor (GIST) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
alpelisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amcasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
apatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ARQ-092 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
binimetinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-285 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
buparlisib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CB-839 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CHMFLKIT-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crenolanib besylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CS-2164 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCC-2618 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infigratinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon gamma-1b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Intuvax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KTN-0158 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
masitinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nilotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NMSP-088 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NRCAN-019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
onalespib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Antagonize GRPR for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pexidartinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLX-9486 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ponatinib hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SF-1126 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-1020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize GPR20 for Acute Myeloid Leukemia and Gastro-Intestinal Stromal Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit c-Kit for Gastrointestinal Stromal Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAS-116 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TGR-1202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vemurafenib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products
Gastrointestinal Stromal Tumor (GIST) - Product Development Milestones
Featured News & Press Releases
Oct 31, 2016: Deciphera Pharmaceuticals to Present Clinical Data on DCC-2618 at 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Jul 13, 2016: Boston Biomedical Announces Generic Name of BBI-503: Amcasertib
May 24, 2016: Arog Pharmaceuticals Presents Crenolanib Clinical Data at the 2016 American Society of Clinical Oncology Annual Meeting
Apr 20, 2016: Kolltan Pharmaceuticals Announces Presentations of Anti-KIT Antibody Preclinical Data at the 2016 American Association for Cancer Research Annual Meeting
Jul 13, 2015: Blueprint Medicines Receives FDA Authorization to Proceed with Clinical Trials for BLU-285
Apr 19, 2015: Blueprint Medicines Presents New Preclinical Data Demonstrating Significant Anti-Tumor Activity of BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets
Apr 08, 2015: Blueprint Medicines to Present New Preclinical Data on BLU-285 in Treatment-Resistant GIST and on Novel Cancer Drug Targets at Upcoming AACR Annual Meeting
Jun 01, 2014: ARIAD Announces Initial Data from Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors
Mar 20, 2014: CHMP Adopts Negative Opinion For AB Science's Masican
Oct 09, 2013: ARIAD Announces Changes in the Clinical Development Program of Iclusig
Jun 11, 2013: Ariad Pharma Initiates Phase II Trial Of Ponatinib In Patients With Gastrointestinal Stromal Tumors
Apr 09, 2013: Ariad Pharma Presents New Preclinical Data Showing Ponatinib Overcomes Resistant Mutations In Oncogenic Driver Of Gastrointestinal Stromal Tumors
Mar 20, 2013: Ariad Pharma Announces Presentations Of Preclinical Data On Iclusig At AACR Annual Meeting
Oct 04, 2012: AB Science Announces Acceptance Of Marketing Application For Masitinib By EMA To Treat Gleevec-resistant Gastro-intestinal Stromal Tumor
Feb 01, 2012: AB Science Reports Encouraging Results From Phase II Study With Its Investigational Drug, Masitinib
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer


LIST OF TABLES

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2016
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by AB Science SA, H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advanced Accelerator Applications S.A., H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Advenchen Laboratories, LLC, H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Ariad Pharmaceuticals, Inc., H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Arog Pharmaceuticals, Inc., H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by ArQule, Inc., H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Array BioPharma Inc., H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Astex Pharmaceuticals Inc, H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Blueprint Medicines Corporation, H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Boston Biomedical, Inc., H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Calithera Biosciences, Inc., H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Chipscreen Biosciences Ltd, H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Horizon Pharma Plc, H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Immunicum AB, H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Natco Pharma Limited, H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Nerviano Medical Sciences S.r.l., H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Novartis AG, H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Omeros Corporation, H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Plexxikon Inc., H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016
Gastrointestinal Stromal Tumor (GIST) - Pipeline by Taiho Pharmaceutical Co., Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Gastrointestinal Stromal Tumor (GIST) - Dormant Projects, H2 2016
Gastrointestinal Stromal Tumor (GIST) - Discontinued Products, H2 2016 197

LIST OF FIGURES

Number of Products under Development for Gastrointestinal Stromal Tumor (GIST), H2 2016
Number of Products under Development for Gastrointestinal Stromal Tumor (GIST) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Ask Your Question

Gastrointestinal Stromal Tumor (GIST) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: